The sustained response rate and clean safety profile support potential for accelerated development and future regulatory engagement. Traders should monitor upcoming data from Cohort 3 and any regulatory feedback later this year as next catalysts.
Price Chart
Executive Summary
Perspective Therapeutics announced updated interim results from its Phase 1/2a trial of [212Pb]VMT-α-NET in neuroendocrine tumors, showing a 43% objective response rate in Cohort 2 with continued favorable safety and deepening responses over time. The data, presented at AACR 2026, includes additional follow-up since prior disclosures at ASCO-GI and ESMO.
Key Facts
- 43% (10 out of 23) objective response rate in Cohort 2 at 5.0 mCi dose level
- No dose-limiting toxicities, treatment-related discontinuations, or serious renal complications reported
- 9 patients experienced deepening of response since ESMO 2025 data cut
- Safety data includes 64 patients across three cohorts with no Grade 5 events
- Additional efficacy data from Cohort 3 expected later in 2026
Financial Impact
Non-financial clinical update, but materially positive for valuation potential given response rate and safety profile in a targeted oncology indication
Risk Factors
- Early-phase data — results may not translate in larger trials
- Regulatory path remains uncertain without Phase 3 plans confirmed
- High market expectations could lead to sell-on-news reaction if next data readout is delayed or muted
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276793 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.61 | awaiting T+20 | — | $1.21 (−24.84%) |
Oct 8, 2026 18d ago | 8-K | $2.71 | awaiting T+20 | — | $1.21 (−55.35%) |
Oct 2, 2026 24d ago | Press Release | $2.76 | awaiting T+20 | — | $1.21 (−56.16%) |
Sep 14, 2026 6w ago | 8-K | $2.92 $2.52 | ▼ −13.70% | ▼ −15.96% | $1.21 (−58.56%) |
Sep 11, 2026 6w ago | Press Release | $2.81 $2.66 | ▼ −5.34% | ▼ −7.21% | $1.21 (−56.94%) |
Sep 8, 2026 6w ago | Insider Cluster | $2.99 $2.46 | ▼ −17.73% | ▼ −19.67% | $1.21 (−59.53%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Sep 4, 2026 7w ago | Insider Cluster | $3.12 $2.36 | ▼ −24.36% | ▼ −26.07% | $1.21 (−61.22%) |
Aug 10, 2026 11w ago | 8-K | $3.18 $2.99 | ▼ −5.97% | ▼ −4.92% | $1.21 (−61.95%) |
Jul 17, 2026 14w ago | Press Release | $2.99 $3.20 | ▲ +7.02% | ▲ +2.58% | $1.21 (−59.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers